MX2023007058A - Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. - Google Patents
Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.Info
- Publication number
- MX2023007058A MX2023007058A MX2023007058A MX2023007058A MX2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- breast cancer
- methods
- estrogen receptor
- treating breast
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 229940125641 estrogen receptor degrader Drugs 0.000 title 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125371P | 2020-12-14 | 2020-12-14 | |
| PCT/US2021/063130 WO2022132652A1 (en) | 2020-12-14 | 2021-12-13 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007058A true MX2023007058A (es) | 2023-06-23 |
Family
ID=79288002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007058A MX2023007058A (es) | 2020-12-14 | 2021-12-13 | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193072A1 (https=) |
| EP (1) | EP4259137A1 (https=) |
| JP (1) | JP2024501471A (https=) |
| KR (1) | KR20230121801A (https=) |
| CN (1) | CN116744925A (https=) |
| AU (1) | AU2021401580A1 (https=) |
| CA (1) | CA3202592A1 (https=) |
| IL (1) | IL303143A (https=) |
| MX (1) | MX2023007058A (https=) |
| TW (1) | TW202237117A (https=) |
| WO (1) | WO2022132652A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN115746058A (zh) * | 2021-09-03 | 2023-03-07 | 南京知和医药科技有限公司 | 一种多环化合物在制备抗肿瘤药物方面的用途 |
| KR20250047743A (ko) * | 2022-07-12 | 2025-04-04 | 리젠츠 오브 더 유니버시티 오브 미시간 | 에스트로겐 수용체 분해제로서의 테트라하이드로나프탈렌 유도체 |
| WO2024049926A1 (en) * | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
| WO2024196053A1 (ko) * | 2023-03-17 | 2024-09-26 | 재단법인 대구경북첨단의료산업진흥재단 | 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물 |
| TW202440096A (zh) * | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| CN121368483A (zh) * | 2023-06-02 | 2026-01-20 | 辉瑞公司 | 雌激素受体降解剂与cdk4抑制剂的组合 |
| EP4719399A1 (en) * | 2023-06-02 | 2026-04-08 | Arvinas Operations, Inc. | Combinations of estrogen receptor degraders and akt inhibitors |
| WO2025122502A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Methods for treating hr-positive her2-negative breast cancer |
| CN121646481A (zh) * | 2024-07-04 | 2026-03-10 | 海创药业股份有限公司 | 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2017507964A (ja) * | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN113164779A (zh) * | 2018-12-06 | 2021-07-23 | 雷迪厄斯制药公司 | 治疗cdk4/6抑制剂耐药性癌症的方法 |
| IL320609A (en) * | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
-
2021
- 2021-12-13 CN CN202180092119.4A patent/CN116744925A/zh active Pending
- 2021-12-13 MX MX2023007058A patent/MX2023007058A/es unknown
- 2021-12-13 WO PCT/US2021/063130 patent/WO2022132652A1/en not_active Ceased
- 2021-12-13 IL IL303143A patent/IL303143A/en unknown
- 2021-12-13 AU AU2021401580A patent/AU2021401580A1/en active Pending
- 2021-12-13 CA CA3202592A patent/CA3202592A1/en active Pending
- 2021-12-13 KR KR1020237023551A patent/KR20230121801A/ko active Pending
- 2021-12-13 EP EP21840327.7A patent/EP4259137A1/en active Pending
- 2021-12-13 US US17/548,842 patent/US20220193072A1/en active Pending
- 2021-12-13 TW TW110146570A patent/TW202237117A/zh unknown
- 2021-12-13 JP JP2023535799A patent/JP2024501471A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202592A1 (en) | 2022-06-23 |
| EP4259137A1 (en) | 2023-10-18 |
| WO2022132652A1 (en) | 2022-06-23 |
| CN116744925A (zh) | 2023-09-12 |
| JP2024501471A (ja) | 2024-01-12 |
| US20220193072A1 (en) | 2022-06-23 |
| AU2021401580A1 (en) | 2023-06-22 |
| IL303143A (en) | 2023-07-01 |
| TW202237117A (zh) | 2022-10-01 |
| KR20230121801A (ko) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007058A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| MX2022002415A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| MX2023006883A (es) | Metodos para tratar el cancer de prostata. | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
| MX2020000268A (es) | Agonista de fxr. | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| NZ790364A (en) | Compounds and compositions for use in treating skin disorders | |
| MX2025007797A (es) | Derivado de tetrahidrotiofeno y uso de este en medicina | |
| MX2022016554A (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida. | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| MX2023004998A (es) | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025002284A (es) | Regímenes de dosificación de degradadores de receptores de estrógeno |